Core Viewpoint - Bavarian Nordic A/S has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million, following the approval of its chikungunya vaccine, VIMKUNYA™ [1] Group 1: Financial Impact - The National Institutes of Health (NIH) will receive 20% of the gross proceeds from the sale of the PRV, which will be recognized as other operating income [2] - The sale proceeds will not impact the guided revenue expectations for 2025, but EBITDA will be positively impacted, with updates on the EBITDA margin of 26-30% for 2025 to be provided upon closing of the transaction [2] Group 2: Transaction Details - The transaction is subject to customary closing conditions, including an anti-trust review expected in the third quarter of 2025 [3] - Jefferies LLC acted as the exclusive financial advisor to Bavarian Nordic for this transaction [3] Group 3: Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, with a strong portfolio in mpox and smallpox vaccines, as well as travel vaccines [4]

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 3 clinical study of its single-dose, virus-like particle (VLP) chikungunya vaccine, CHIKV VLP in children 2 to 11 years of age. This first trial of CHIKV VLP in a pediatric population aims to expand the target population for the vaccine, currently approved for persons 12 years of age and ...

COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for VIMKUNYA® (recombinant, adsorbed) for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older. The vaccine was approved following MHRA review under the international recognition procedure, which is a targeted assessment that recognize ...